[{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"268eae36-cdca-45ae-8506-36b3e8cbd7f6","acronym":"BLAST MRD AML-2","url":"https://clinicaltrials.gov/study/NCT04284787","created_at":"2024-03-22T03:46:14.077Z","updated_at":"2025-02-25T17:00:27.213Z","phase":"Phase 2","brief_title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04284787 - BLAST MRD AML-2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • Chr t(15;17)","tags":["PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"25d126ed-adfd-4904-90fa-0ad4d4e4b4f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06755775","created_at":"2025-02-26T07:41:22.376Z","updated_at":"2025-02-26T07:41:22.376Z","phase":"","brief_title":"PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT06755775","lead_sponsor":"Ruijin Hospital","biomarkers":" GZMB","pipe":"","alterations":" ","tags":["GZMB"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 07/23/2029","primary_completion_date":" 07/23/2029","study_txt":" Completion: 07/23/2029","study_completion_date":" 07/23/2029","last_update_posted":"2025-01-01"},{"id":"50327f9a-1abf-4371-9c4a-df172130c528","acronym":"GzmB-PET4BC","url":"https://clinicaltrials.gov/study/NCT06725940","created_at":"2025-02-26T10:09:41.912Z","updated_at":"2025-02-26T10:09:41.912Z","phase":"","brief_title":"GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer","source_id_and_acronym":"NCT06725940 - GzmB-PET4BC","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" GZMB","pipe":"","alterations":" ","tags":["GZMB"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-12-10"},{"id":"15ea0b15-7362-42f9-a5c9-83b6fa5b6dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451982","created_at":"2021-01-18T11:45:29.420Z","updated_at":"2025-02-25T14:35:37.102Z","phase":"Phase 2","brief_title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT02451982","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • PD-1 • TNFRSF9 • GZMB • IL17A","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TNFRSF9 • GZMB • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-06"},{"id":"fe6e795f-22fd-4cd7-b9e7-1f7eb8efecb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06700070","created_at":"2025-02-26T12:47:00.042Z","updated_at":"2025-02-26T12:47:00.042Z","phase":"Phase 1","brief_title":"A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors","source_id_and_acronym":"NCT06700070","lead_sponsor":"Pure Biologics S.A.","biomarkers":" TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["TNFA • CASP3 • GZMB • CD86"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-11-21"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"f457b6dc-bf69-44d9-a56c-049a2a1cb232","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111941","created_at":"2024-01-03T19:17:22.178Z","updated_at":"2024-07-02T16:34:38.080Z","phase":"Phase 1","brief_title":"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02111941","lead_sponsor":"Mayo Clinic","biomarkers":" IFNG • TNFA • IL10 • GZMB • IL17A","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • GZMB • IL17A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 07/27/2021","primary_completion_date":" 07/27/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"03e89ab8-dacb-455b-84eb-7a4c304f5cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06338657","created_at":"2024-03-29T14:40:53.948Z","updated_at":"2024-07-02T16:35:02.933Z","phase":"Phase 1","brief_title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","source_id_and_acronym":"NCT06338657","lead_sponsor":"University of Southern California","biomarkers":" PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • LAG3 • CD38 • TIGIT • CCR7 • GZMB • BTLA • PRDM1 • CXCR3 • SIGLEC15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nanoencapsulated paclitaxel (FID-007)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-17"},{"id":"9d91719c-a4f8-489a-a4f8-f503e0f382e7","acronym":"PBL-0405-01","url":"https://clinicaltrials.gov/study/NCT06273852","created_at":"2024-02-23T16:26:42.227Z","updated_at":"2024-07-02T16:35:03.110Z","phase":"Phase 1","brief_title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","source_id_and_acronym":"NCT06273852 - PBL-0405-01","lead_sponsor":"Pure Biologics S.A.","biomarkers":" ROR1 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["ROR1 • TNFA • CASP3 • GZMB • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"ce6acbdf-d0c9-46e4-a247-444e713619ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413095","created_at":"2024-05-18T04:21:47.057Z","updated_at":"2025-02-25T16:02:48.188Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","source_id_and_acronym":"NCT06413095","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • IFNG • CD163 • GZMB","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD163 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 06/22/2023","study_completion_date":" 06/22/2023","last_update_posted":"2024-05-14"},{"id":"1d4dd198-7dd9-44b5-bf2f-70642e346bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06400160","created_at":"2024-05-11T04:34:11.020Z","updated_at":"2024-07-02T16:35:05.740Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","source_id_and_acronym":"NCT06400160","lead_sponsor":"Twinpig Biolab, Inc.","biomarkers":" CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2","pipe":" | ","alterations":" IL2-L","tags":["CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-06"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"821ba445-ef11-495f-8892-3f8670ca41f4","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT04939480","created_at":"2021-06-25T22:54:07.374Z","updated_at":"2024-07-02T16:35:07.670Z","phase":"Phase 2","brief_title":"Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN","source_id_and_acronym":"NCT04939480 - PIONEER","lead_sponsor":"University Hospital, Essen","biomarkers":" GZMB","pipe":" | ","alterations":" NCAM1 positive","tags":["GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 03/14/2024","primary_completion_date":" 03/14/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-04-25"},{"id":"14763699-a9a1-4656-939a-4ccb4819119b","acronym":"BIS-Program","url":"https://clinicaltrials.gov/study/NCT05180006","created_at":"2022-01-06T23:53:44.740Z","updated_at":"2025-02-25T12:28:33.945Z","phase":"Phase 2","brief_title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","source_id_and_acronym":"NCT05180006 - BIS-Program","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • PGR • GZMB","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression","tags":["HER-2 • PGR • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-18"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"b525caf0-9878-4941-940b-34047b6f9445","acronym":"","url":"https://clinicaltrials.gov/study/NCT05000372","created_at":"2023-11-29T17:15:06.500Z","updated_at":"2024-07-02T16:35:09.780Z","phase":"Phase 1/2","brief_title":"68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy","source_id_and_acronym":"NCT05000372","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" GZMB","pipe":"","alterations":" ","tags":["GZMB"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/22/2021","start_date":" 09/22/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-04-15"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Istodax (romidepsin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"52cec249-3dea-47ff-af14-c5976f1922da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05604560","created_at":"2022-11-03T14:56:55.660Z","updated_at":"2024-07-02T16:35:14.598Z","phase":"Phase 2","brief_title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","source_id_and_acronym":"NCT05604560","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9 • GZMB","pipe":"","alterations":" ","tags":["TNFRSF9 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/08/2023","start_date":" 11/08/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-15"},{"id":"4c303da3-0333-482c-a447-3a810066c7aa","acronym":"AMBUSH","url":"https://clinicaltrials.gov/study/NCT05514990","created_at":"2023-11-18T23:15:37.982Z","updated_at":"2024-07-02T16:35:28.859Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","source_id_and_acronym":"NCT05514990 - AMBUSH","lead_sponsor":"University of Southern California","biomarkers":" CD8 • PD-1 • IFNG • CD4 • GZMB","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bortezomib • Reolysin (pelareorep) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2026","study_completion_date":" 10/07/2026","last_update_posted":"2023-11-17"},{"id":"69708668-cfc0-4439-a660-502e583a10e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05483075","created_at":"2022-08-01T14:54:50.589Z","updated_at":"2024-07-02T16:35:29.781Z","phase":"","brief_title":"Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer","source_id_and_acronym":"NCT05483075","lead_sponsor":"NYU Langone Health","biomarkers":" CD8 • GZMB","pipe":" | ","alterations":" CD8 expression • CD8 positive","tags":["CD8 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD8 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-09"}]